Roman Axelrod balances what appears to be an ordinary contact lens on his fingertip in a Dubai laboratory. Look closer—embedded inside are circuits thinner than spider silk, a microdisplay smaller than a rice grain, sensors capable of reading tear fluid's chemical composition. It's one of fifteen working prototypes his company XPANCEO has assembled in twenty-four months, each addressing a different fragment of what may be the most audacious wearable technology ever conceived.
Perhaps more audacious than Axelrod expected. His Dubai-based startup just crossed into unicorn territory this past July with a $250 million Series A, hitting a $1.35 billion valuation. That plants serious capital behind a product category littered with corpses. Google's glucose-sensing lens project collapsed in 2018 after researchers couldn't extract reliable readings from tear fluid. Mojo Vision, once the darling of augmented reality contact lenses, pivoted away from the technology in early 2023 and shed roughly 75% of its workforce.
XPANCEO believes it understands why those efforts crumbled. Instead of cramming everything into one device from the outset, the company built separate prototypes for each function—and only now is working to integrate them. The approach has yielded tangible results journalists could actually test at Mobile World Congress 2025, where the lenses collected eight "Best of" awards from outlets including TechRadar and SlashGear.
Prototypes That Work (So Far)
At MWC 2025, XPANCEO unveiled three new prototypes demonstrating genuine technical progress. The first employs wireless power transfer from a companion device—a small puck users would carry—that the company claims offers double the range of comparable solutions with radiation levels similar to headphones. Whether those safety claims survive independent testing remains uncertain, but power is flowing to a contact lens without wires. That counts for something.
The second prototype tackles glaucoma monitoring through an optical pattern on the lens surface. A smartphone app with AI trained on more than 10,000 intraocular pressure measurements reads that pattern and infers eye pressure, potentially catching the disease before irreversible vision loss occurs. XPANCEO calls it "medical-grade sensitivity," though that designation awaits FDA validation.
The third merges a microdisplay with holographic optics to project AR content at a virtual focal distance. At GITEX Asia in Singapore, XPANCEO demonstrated this system with a 52-degree field of view. Wired's reporter actually peered through an AR lens prototype and could read text—though they cautioned it would be "a long while" before anything reaches consumers. The honesty was refreshing.
Beyond those three, XPANCEO showed biochemical sensors at MWC targeting glucose, cortisol, sex hormones like estradiol and testosterone, and vitamins B1, B2, B3, D, and E—all theoretically detectable in tear fluid. There's also a data-reading lens with an integrated wireless antenna transmitting information to a phone.
The prototype count itself tells a story about iteration velocity. XPANCEO constructed its first testing system for AR holographic lenses in February 2024. By September 2024, they'd partnered with Konica Minolta on what they termed the "world's first system for testing AR contact lenses." Another collaboration with JBD integrated a microdisplay and tested different optical approaches for solving the fundamental problem that human eyes can't focus closer than five to seven centimeters.
Medical Device Path, Not Consumer Gadget
Here's where it gets interesting: XPANCEO's regulatory strategy. The company isn't positioning these as consumer gadgets. From day one, they've treated the lenses as medical devices requiring biocompatibility testing and clinical validation.
Dr. Valentyn S. Volkov, the physicist serving as CTO and scientific partner, has assembled a scientific advisory board chaired by Nobel laureate Sir Konstantin Novoselov. The company is collaborating with the University of Manchester, National University of Singapore, and Donostia International Physics Center on materials science challenges—like creating the world's thinnest flexible gold conductors for transparent electronics.
In September 2025, XPANCEO and INTRA-KER unveiled an intracorneal implant prototype that projects images to the retina, tested in a donor human eye. That's not a contact lens, but it demonstrates the team is thinking through surgical implant pathways, not just wearables.
The go-to-market plan shows strategic thinking. According to Business Insider's July 2025 interview with founders, XPANCEO plans to consolidate its prototypes into one integrated lens by early 2027, then pursue FDA approval. But instead of waiting for full consumer clearance, they'll commercialize narrow medical use cases first. The IOP monitoring system for glaucoma could potentially launch as early as 2028 in B2B settings.
Broad consumer availability wouldn't arrive until the early 2030s.
That timeline allows them to build revenue while navigating the regulatory maze. Sensimed's Triggerfish IOP monitoring lens, which measures ocular dimensional changes over 24 hours, gained CE mark approval in 2010 and FDA authorization in 2016. XPANCEO is attempting something far more complex, but at least there's precedent for getting eye-worn medical devices past regulators.
The Technical Gauntlet Ahead
The challenges here are not subtle.
XPANCEO needs to integrate a display system, multiple biosensors, wireless power transfer, data transmission, and control interfaces into a soft lens that's safe for all-day wear on the human cornea. Power remains the killer problem. IEEE Spectrum's April 2024 overview of smart contact lens power systems laid out the core issue: you need sufficient energy to run displays and sensors without heating the cornea.
XPANCEO's wireless power transfer concept with a companion device offers one path. They demonstrated a space-ready variant in December 2025 that draws power from a helmet integrated with an actual space suit. That space prototype, being tested with Dubai's Mohammed Bin Rashid Space Centre, reveals practical thinking about use cases. Smart glasses would be hazardous in zero gravity, and gloves make touchscreens impractical. A contact lens placing data in the astronaut's direct line of sight could actually solve real problems. Ground tests began in December 2025, with plans for parabolic flights and potential in-orbit validation.
The materials science is equally demanding. XPANCEO published research in ACS Nano in June 2025 on producing nanoparticles from more than 50 van der Waals materials, which underpins their approach to color filtering and enhancement features. The company claims these nanoparticle-based systems will enable "night vision" and optical zoom—though those features haven't been independently demonstrated by journalists yet.
Marketing Vision Versus Current Reality
XPANCEO describes its vision as "one infinite screen" that merges all devices into a single, invisible interface controlled by eye tracking, voice, or even tongue gestures. The marketing emphasizes superpowers: night vision letting you see in darkness, zoom capabilities extending your visual range, continuous health monitoring tracking everything from glucose to hormones.
In a September 2025 interview with an ophthalmology trade publication, the company said they're targeting a cost "comparable to a smartphone" for an annual supply of replaceable smart lenses. That's deliberately vague but suggests they're thinking hundreds of dollars, not thousands.
At October 2025's GITEX Global in Dubai, the company presented six prototypes simultaneously and opened an extended lab for tours. That public transparency around hardware is unusual for a startup at this stage—perhaps reflecting confidence, perhaps a recognition that credibility requires showing actual devices.
Running Unopposed
XPANCEO is essentially operating without competition in smart contact lenses right now. Mojo Vision's pivot left the field wide open. Innovega's contact lens plus glasses system for low vision and AR has been in development for years but remains pre-commercial, with FAQs citing a target of 2026 for trials contingent on FDA clearance. Azalea Vision is working on adaptive optics for photophobia and presbyopia but with a narrower scope.
That void exists because the technical barriers are genuine. Multiple market research reports cite battery constraints, privacy and security concerns, and high regulatory costs as persistent obstacles. The fact that nobody else has cracked this suggests either that XPANCEO has breakthrough approaches, or that the market is about to learn expensive lessons. Maybe both.
The team composition offers some reassurance. Beyond Axelrod and Volkov, the company employs around 100 people and raised a $40 million seed round led by Opportunity Venture in October 2023 before the recent $250 million Series A from the same lead investor. That kind of capital concentration with one major backer could be a red flag—or could mean deep pockets for a long regulatory journey.
The Verification Gap
There's a gap between what XPANCEO has demonstrated and what it claims is coming.
Journalists at MWC 2025 saw working AR displays, biosensing panels, and the IOP measurement system. Multiple outlets confirmed these functions existed in prototype form. But night vision and zoom remain marketing promises rather than independently verified features. The wireless power transfer claim of "2× range" and "completely safe" exposure hasn't been validated in public literature. The 52-degree field of view for the AR display comes from the company's own GITEX Asia demonstration, not independent lab testing.
That doesn't mean the claims are false. It means they're unverified.
XPANCEO is making the right noises about regulatory rigor and clinical validation. The question is whether the technology can actually integrate into one biocompatible, all-day-wear lens by their end-of-2026 target. Getting separate prototypes to work in controlled demos is one thing. Combining holographic displays, multiple biosensors, wireless power, and data transmission into a single soft lens that doesn't cook your cornea? Something else entirely.
The regulatory timeline adds years. If XPANCEO hits its early 2027 integration milestone, they'd still need to design clinical trials, submit investigational device exemptions, run the studies, and wait for FDA review. That's why they're talking about 2028 for narrow medical deployments and early 2030s for consumer launch.
Why This Matters
For healthtech investors and medical device companies watching this space, XPANCEO represents an interesting test case. They're attempting to succeed where Google failed by taking a medical device path with narrower initial applications rather than swinging for a broad consumer product. They've demonstrated enough working hardware to prove they're serious engineers, not just slideware. And they've raised enough capital to actually fund the long journey through clinical trials and regulatory approval.
Whether that's enough remains an open question.
But at minimum, XPANCEO has turned smart contact lenses from science fiction into an engineering problem that might—just might—have solutions. The company has moved the conversation from "if" to "how." That shift alone justifies watching what happens next, even if the early 2030s timeline means most of us will be waiting a while before we're reading emails off our eyeballs.
The real test comes in late 2026, when all those separate prototypes either converge into one functioning lens or reveal themselves as a collection of promising fragments that can't quite merge. Until then, XPANCEO remains the unicorn betting it can see what others missed.
